{
  "disease_name": "Endometrial cancer",
  "synonyms": [
    "Uterine cancer",
    "Endometrial carcinoma"
  ],
  "summary": "Endometrial cancer arises from the lining of the uterus and is the most common gynecologic malignancy in developed countries. It is primarily classified into Type I (estrogen-dependent, endometrioid histology, favorable prognosis) and Type II (non-estrogen-dependent, serous or clear cell histology, aggressive).",
  "causes": [
    "Excess estrogen exposure",
    "PTEN mutation",
    "TP53 mutation",
    "PIK3CA mutation",
    "KRAS mutation",
    "CTNNB1 mutation",
    "Mismatch repair gene defects (MLH1, MSH2, MSH6, PMS2) in Lynch syndrome"
  ],
  "risk_factors": [
    "Obesity",
    "Diabetes mellitus",
    "Hypertension",
    "Unopposed estrogen therapy",
    "Early menarche",
    "Late menopause",
    "Nulliparity",
    "Tamoxifen use",
    "Polycystic ovary syndrome",
    "Lynch syndrome"
  ],
  "symptoms": [
    "Postmenopausal bleeding",
    "Abnormal vaginal bleeding",
    "Pelvic pain",
    "Dyspareunia",
    "Painful urination",
    "Abdominal pain",
    "Pelvic mass"
  ],
  "diagnosis": [
    "Endometrial biopsy",
    "Dilation and curettage (D&C)",
    "Transvaginal ultrasound",
    "MRI for staging",
    "CA-125 marker",
    "Histopathology (grade and type)",
    "FIGO staging system"
  ],
  "treatments": [
    "Total hysterectomy with bilateral salpingo-oophorectomy",
    "Lymphadenectomy (for high-grade or advanced disease)",
    "Radiotherapy (brachytherapy or external beam)",
    "Chemotherapy (carboplatin, paclitaxel, doxorubicin)",
    "Hormonal therapy (progestins, medroxyprogesterone, megestrol acetate)",
    "Targeted therapy (mTOR inhibitors, bevacizumab, PARP inhibitors)",
    "Immunotherapy (dostarlimab for mismatch repair-deficient tumors)"
  ],
  "related_genes": [
    "PTEN",
    "TP53",
    "PIK3CA",
    "KRAS",
    "CTNNB1",
    "ARID1A",
    "MLH1",
    "MSH2",
    "MSH6",
    "PMS2",
    "HER2"
  ],
  "subtypes": [
    {
      "name": "Type I (Endometrioid carcinoma)",
      "typical_patients": "Perimenopausal women; associated with estrogen exposure and obesity",
      "five_year_survival": "≈85–90% (early stage)",
      "common_treatments": [
        "Surgery",
        "Progestin therapy",
        "Chemoradiation (advanced)"
      ]
    },
    {
      "name": "Type II (Serous and Clear cell carcinoma)",
      "typical_patients": "Older postmenopausal women; not associated with estrogen",
      "five_year_survival": "≈40–50% (early stage)",
      "common_treatments": [
        "Surgery",
        "Chemotherapy",
        "Radiation therapy"
      ]
    },
    {
      "name": "Endometrial stromal sarcoma",
      "typical_patients": "Middle-aged women; slow-growing tumor",
      "five_year_survival": "60–90% (low-grade)",
      "common_treatments": [
        "Surgery",
        "Hormonal therapy"
      ]
    }
  ],
  "epidemiology": {
    "global_cases_2015": "320000",
    "global_deaths_2015": "76000",
    "most_common_in": "Postmenopausal women; more frequent in developed countries",
    "five_year_survival_rate": "≈80% overall (US)"
  },
  "relationships": [
    {
      "source": "Endometrial cancer",
      "relation": "has_symptom",
      "target": "Postmenopausal bleeding"
    },
    {
      "source": "Endometrial cancer",
      "relation": "has_symptom",
      "target": "Pelvic pain"
    },
    {
      "source": "Endometrial cancer",
      "relation": "has_symptom",
      "target": "Abnormal vaginal bleeding"
    },
    {
      "source": "Endometrial cancer",
      "relation": "has_cause",
      "target": "Excess estrogen exposure"
    },
    {
      "source": "Endometrial cancer",
      "relation": "has_risk_factor",
      "target": "Obesity"
    },
    {
      "source": "Endometrial cancer",
      "relation": "has_risk_factor",
      "target": "Diabetes mellitus"
    },
    {
      "source": "Endometrial cancer",
      "relation": "has_risk_factor",
      "target": "Tamoxifen use"
    },
    {
      "source": "Endometrial cancer",
      "relation": "associated_gene",
      "target": "PTEN"
    },
    {
      "source": "Endometrial cancer",
      "relation": "associated_gene",
      "target": "TP53"
    },
    {
      "source": "Endometrial cancer",
      "relation": "associated_gene",
      "target": "PIK3CA"
    },
    {
      "source": "Endometrial cancer",
      "relation": "associated_gene",
      "target": "KRAS"
    },
    {
      "source": "Endometrial cancer",
      "relation": "associated_gene",
      "target": "CTNNB1"
    },
    {
      "source": "Endometrial cancer",
      "relation": "treated_with",
      "target": "Hysterectomy"
    },
    {
      "source": "Endometrial cancer",
      "relation": "treated_with",
      "target": "Chemotherapy"
    },
    {
      "source": "Endometrial cancer",
      "relation": "treated_with",
      "target": "Radiation therapy"
    },
    {
      "source": "Endometrial cancer",
      "relation": "treated_with",
      "target": "Hormonal therapy"
    },
    {
      "source": "Endometrial cancer",
      "relation": "treated_with",
      "target": "Immunotherapy"
    },
    {
      "source": "Type I (Endometrioid carcinoma)",
      "relation": "subtype_of",
      "target": "Endometrial cancer"
    },
    {
      "source": "Type II (Serous and Clear cell carcinoma)",
      "relation": "subtype_of",
      "target": "Endometrial cancer"
    },
    {
      "source": "Endometrial stromal sarcoma",
      "relation": "subtype_of",
      "target": "Endometrial cancer"
    }
  ]
}